CLINICAL RESEARCH: HEART FAILURE
A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure
Gabriele Fragasso, MD*,1,*,
Altin Palloshi, MD*,
Patrizia Puccetti, MD*,
Carmen Silipigni, MD*,
Alessandra Rossodivita, MD ,
Mariagrazia Pala, MD,
Giliola Calori, MDPhD*,
Ottavio Alfieri, MD* and
Alberto Margonato, MD, FESC*
* Clinical Cardiology-Heart Failure Unit, Istituto Scientifico-Universita Vita/Salute San Raffaele, Milan, Italy.
Cardiac Surgery, Istituto Scientifico-Universita Vita/Salute San Raffaele, Milan, Italy.
Manuscript received October 27, 2005;
revised manuscript received March 3, 2006,
accepted March 30, 2006.
* Reprint requests and correspondence: Dr. Gabriele Fragasso, Clinical Cardiology-Heart Failure Unit, Istituto Scientifico-Universita Vita/Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy. (Email: gabriele.fragasso{at}hsr.it).
OBJECTIVES: This study sought to assess whether the long-term addition of trimetazidine to conventional treatment could improve functional class, exercise tolerance, and left ventricular function in patients with heart failure (HF).
BACKGROUND: Previous small studies have shown that trimetazidine may be beneficial in terms of left ventricular function preservation and control of symptoms in patients with post-ischemic HF.
METHODS: Fifty-five patients with HF were randomly allocated in an open-label fashion to either conventional therapy plus trimetazidine (20 mg three times daily) (28 patients) or conventional therapy alone (27 patients). Mean follow-up was 13 ± 3 months. At study entry and at follow-up, all patients underwent exercise testing and two-dimensional echocardiography. Among the others, New York Heart Association (NYHA) functional class and ejection fraction (EF) were evaluated.
RESULTS: In the trimetazidine group, NYHA functional class significantly improved compared with the conventional therapy group (p < 0.0001). Treatment with trimetazidine significantly decreased left ventricular end-systolic volume (from 98 ± 36 ml to 81 ± 27 ml, p = 0.04) and increased EF from 36 ± 7% to 43 ± 10% (p = 0.002). On the contrary, in the conventional therapy group, both left ventricular end-diastolic and -systolic volumes increased from 142 ± 43 ml to 156 ± 63 ml, p = 0.2, and from 86 ± 34 ml to 104 ± 52 ml, p = 0.1, respectively; accordingly, EF significantly decreased from 38 ± 7% to 34 ± 7% (p = 0.02).
CONCLUSIONS: In conclusion, long-term trimetazidine improves functional class and left ventricular function in patients with HF. This benefit contrasts with the natural history of the disease, as shown by the decrease of EF in patients on standard HF therapy alone.
|
Abbreviations and Acronyms
| | ATP = adenosine triphosphate | | BNP = brain natriuretic peptide | | EDV = end-diastolic volume | | EF = ejection fraction | | ESV = end-systolic volume | | FFA = free fatty acids | | HF = heart failure | | METS = metabolic equivalent system | | NYHA = New York Heart Association |
|
Related Article
-
Metabolic Approach in Heart Failure: Rethinking How We Translate From Theory to Clinical Practice
- W.H. Wilson Tang
J. Am. Coll. Cardiol. 2006 48: 999-1000.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
H. Ardehali, H. N. Sabbah, M. A. Burke, S. Sarma, P. P. Liu, J. G. F. Cleland, A. Maggioni, G. C. Fonarow, E. D. Abel, U. Campia, et al.
Targeting myocardial substrate metabolism in heart failure: potential for new therapies
Eur J Heart Fail,
February 1, 2012;
14(2):
120 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Fragasso, A. Salerno, G. Lattuada, A. Cuko, G. Calori, A. Scollo, F. Ragogna, F. Arioli, G. Bassanelli, R. Spoladore, et al.
Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure
Heart,
September 15, 2011;
97(18):
1495 - 1500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Lionetti, W. C. Stanley, and F. A. Recchia
Modulating fatty acid oxidation in heart failure
Cardiovasc Res,
May 1, 2011;
90(2):
202 - 209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tuunanen and J. Knuuti
Metabolic remodelling in human heart failure
Cardiovasc Res,
May 1, 2011;
90(2):
251 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gao, N. Ning, X. Niu, G. Hao, and Z. Meng
Trimetazidine: a meta-analysis of randomised controlled trials in heart failure
Heart,
February 15, 2011;
97(4):
278 - 286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Liu, Y. Gai, F. Liu, W. Gao, Y. Zhang, M. Xu, and Z. Li
Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway
Cardiovasc Res,
October 1, 2010;
88(1):
150 - 158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Zemljic, M. Bunc, and B. Vrtovec
Trimetazidine Shortens QTc Interval in Patients With Ischemic Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2010;
15(1):
31 - 36.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Cera, A. Salerno, G. Fragasso, C. Montanaro, C. Gardini, G. Marinosci, F. Arioli, R. Spoladore, A. Facchini, C. Godino, et al.
Beneficial Electrophysiological Effects of Trimetazidine in Patients With Postischemic Chronic Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2010;
15(1):
24 - 30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley
Myocardial Fatty Acid Metabolism in Health and Disease
Physiol Rev,
January 1, 2010;
90(1):
207 - 258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. T. Phan, G. N. Shivu, A. Choudhury, K. Abozguia, C. Davies, U. Naidoo, I. Ahmed, Z. Yousef, J. Horowitz, and M. Frenneaux
Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope
Eur J Heart Fail,
September 1, 2009;
11(9):
881 - 886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Scheuer
Letter by Scheuer Regarding Article, "Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy"
Circulation,
March 24, 2009;
119(11):
e371 - e371.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse
Metabolic remodelling of the failing heart: beneficial or detrimental?
Cardiovasc Res,
February 15, 2009;
81(3):
420 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Qanud, M. Mamdani, M. Pepe, R. J. Khairallah, J. Gravel, B. Lei, S. A. Gupte, V. G. Sharov, H. N. Sabbah, W. C. Stanley, et al.
Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure
Am J Physiol Heart Circ Physiol,
November 1, 2008;
295(5):
H2098 - H2105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, K.E. Juhani Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, et al.
Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy
Circulation,
September 16, 2008;
118(12):
1250 - 1258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler
Reply
J. Am. Coll. Cardiol.,
July 15, 2008;
52(3):
239 - 240.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler
Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
93 - 102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Pilz, H. Scharnagl, B. Tiran, B. Wellnitz, U. Seelhorst, B. O. Boehm, and W. Marz
Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography
Eur. Heart J.,
November 2, 2007;
28(22):
2763 - 2769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie
Metabolic Mechanisms in Heart Failure
Circulation,
July 24, 2007;
116(4):
434 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W H Fung, C. C Szeto, and C. M Yu
Preventing contrast nephropathy in catheter laboratory
Heart,
June 1, 2007;
93(6):
654 - 655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Metra, P. Ponikowski, K. Dickstein, J. J.V. McMurray, A. Gavazzi, C.-H. Bergh, A. G. Fraser, T. Jaarsma, A. Pitsis, P. Mohacsi, et al.
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail,
June 1, 2007;
9(6-7):
684 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Fragasso, A. Palloshi, and G. Perseghin
Letter by Fragasso et al Regarding Article by Tuunanen et al, "Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure"
Circulation,
May 29, 2007;
115(21):
e546 - e546.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Labinskyy, M. Bellomo, M. P. Chandler, M. E. Young, V. Lionetti, K. Qanud, F. Bigazzi, T. Sampietro, W. C. Stanley, and F. A. Recchia
Chronic Activation of Peroxisome Proliferator-Activated Receptor-{alpha} with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure
J. Pharmacol. Exp. Ther.,
April 1, 2007;
321(1):
165 - 171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang
Metabolic Approach in Heart Failure: Rethinking How We Translate From Theory to Clinical Practice
J. Am. Coll. Cardiol.,
September 5, 2006;
48(5):
999 - 1000.
[Full Text]
[PDF]
|
|
|
|
